1. ZERO HUMANS have been dosed right now! I plan on lifting weights in 4 weeks. Does that make me Mr Universe now?! 2. Passing GLP does not "derisk" phase 1 studies. GLP is mandatory. No Phase 1 study will start without passing GLP. Nothing is "derisked", otherwise why bother with Phase 1! Successfully completing phase 1 is the only thing that will "de risk" phase 1. 3. It doesn't do any of these things IN HUMANS. Dozens and dozens of preclinical compounds do this in rats, mice, and test tubes. 4. A patent "submitted" is not IP protection or a patent granted. Less than half of patents get approved. Patents take YEARS and YEARS. 5. OK, show us where the CEO has said they have locked in non dilutive funding. Be specific. 6. They've got less than 4 million in the bank, 7. So if anything this makes it more risky in safety and phase 1. More risk. Increased risk. Non de-risked risky McRisk with a side order of risk. 8. YES! You're getting it. Peers that have cleared phase 1, with a pipeline, IP protection, actual funding in place, without a track record of failure, are worth 100m. Nyrada is none of these things.
NYR Price at posting:
14.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)